EMA/716713/2010

European Medicines Agency decision

P/6/2011

of 3 January 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for midostaurin, (EMEA-000780-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/6/2011

of 3 January 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for midostaurin, (EMEA-000780-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Novartis Europharm Ltd on 14 December 2009 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation, and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 November 2010, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and with Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for midostaurin, oral solution, soft capsule, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for midostaurin, oral solution, soft capsule, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A product-specific waiver for midostaurin, oral solution, soft capsule, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Novartis Europharm Ltd, Wimblehurst Road, RH12 5AB Horsham, United Kingdom.

Done at London, 3 January 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director

(Signature on file)

EMA/PDCO/662073/2010

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-000780-PIP01-09

Scope of the application

Active substance(s):

Midostaurin

Condition(s):

Treatment of acute myeloid leukaemia

Treatment of malignant mastocytosis

Treatment of mast cell leukaemia

Pharmaceutical form(s):

Oral solution

Soft capsule

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Ltd submitted for agreement to the European Medicines Agency on 14 December 2009 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 21 January 2010.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Supplementary information was provided by the applicant on 26 August 2010.

A meeting with the Paediatric Committee took place on 10 November 2010.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation,
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with

     Articles 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population and

     Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 12 November 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of acute myeloid leukaemia

The waiver applies to:

- Paediatric population from birth to less than 3 months of age
- for oral solution and soft capsule for oral use
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

1.2. Conditions: Treatment of malignant mastocytosis and of mast cell leukaemia

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age
- for oral solution and soft capsule for oral use
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: Treatment of acute myeloid leukaemia

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with FLT3 mutated AML, newly diagnosed or in first relapse.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Oral solution

Soft capsule

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable
Non-clinical	1	Study 1: Juvenile development study

Area	Number of studies	Description
Clinical	3	Study 2: Open-label, dose-escalating, single-agent, multi-centre, age-stratified trial to evaluate toxicity, pharmacokinetics, pharmacodynamics, safety and activity of midostaurin in children from 3 months to less than 18 years of age with refractory or relapse acute lymphoblastic or acute myeloid leukaemia Study 3: Open-label, dose-escalating, randomised, active-controlled, age-stratified, multi-centre trial to evaluate toxicity, pharmacokinetics, pharmacodynamics, safety and activity in children from 3 months to less than 18 years of age with newly-diagnosed acute myeloid leukaemia with certain FLT3 TKD mutation burden Study 4: Population pharmacokinetic / pharmacodynamic and outcome model to support extrapolation of efficacy

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2019
Deferral for one or more studies contained in the paediatric investigation plan:	Yes